Jun 16, 2022
The company has strong ratings for value, growth, and momentum
We recommend buying Moderna’s value for long-term investment
Moderna Inc. (NASDAQ:MRNA) is trading at $128. The price is just below the support level of $140. Our analysis shows that the bear market explains the pressure on the support level. This week, the stock is bullish. We think it is a buy.
Moderna has the greatest advantage of having a low PE. For the EPS of $36.28, the forward PE is 3.57. The company is expected to grow its EPS this year though the revenue may decline towards the end of the year. Going forward, the company needs to develop new products to sustain growth. The medium-term growth rate is expected at 6.5%.
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
Moderna presents a good investment opportunity. The A-rating on growth, value, and momentum makes the stock attractive. Other pricing indicators such as the PEG ratio at $0.69, indicating that the stock is undervalued. This analysis considers Moderna a strong buy.
Moderna shows support at $130 and resistance at $180
Source – TradingView
Technical analysis shows that Moderna has sustainable support at $140. Though the support level has already been tested, we project that the stock will find its way up. The RSI at 37 is close to the oversold trigger. The MACD is mildly bullish in the midst of a bear market. We recommend buying Moderna at $128. The target price is $180 as the stock consolidates.
Moderna has low PE and PEG ratios indicating that the stock is undervalued. The EPS of $36 is projected to grow by at least 6.5% annually for the next 3-5 years. The stock will sustain support at $140 and resistance at $180.
Where to buy right now
To invest simply and easily, users need a low-fee broker with a track record of reliability. The following brokers are highly rated, recognised worldwide, and safe to use:
*Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
Health & pharmaceuticals
Stocks & Shares